Advanced Search


Study ID Status Title Patient Level Data
LAM-2003-01 Completed Validation Of Qolie-10 For Epilepsy, Comparison Of Quality Of Life In Patients Treated With Lamotrigine Or Valproic Acid
LAM30055 Completed A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures Study Listed on
LAM40013 Completed A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients with Epilepsy Study Listed on
LAM40097 Completed A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Evaluation of Lamotrigine Adjunctive Therapy in Subjects wtih Primary Generalized Tonic-Clonic Seizures Study Listed on
LAV104616 Completed A randomized, double-blind, four period cross-over comparison of the effect of two doses lavoltidine, esomeprazole, and placebo on 24 hour gastric pH and frequency of heartburn in symptomatic GERD subjects without esophageal erosions
LAV110285 Completed An Open-Label study of the Development of Pharmacodynamic Tolerance to 7-days Administration of Lavoltidine 40mg
LBI108245 Completed A multi-centre, observational study to evaluate the incidence of non-serious rash in Korean bipolar I patients with lamotrigine therapy in real world setting
LBI108614 Completed An open-label, randomised, single-dose, parallel-group study to evaluate the pharmacokinetic characteristics, safety and tolerability of up to two formulations (with different taste masking approaches) of an orally disintegrating tablet (ODT) of lamotrigine at 25mg and 200mg versus the immediate release (IR) lamotrigine in healthy subjects Study Listed on
LBI108617 Completed An open-label, randomised, single-dose, parallel-group study to demonstrate bioequivalence of two formulations and the effect of food and water on one formulation of lamotrigine in healthy male and female volunteers Study Listed on
LBI108884 Completed An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder Study Listed on
LEP103944 Completed An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine when Switching Patients with Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa Study Listed on
LEP105972 Completed Lamotrigine Extended-Release in Elderly Patients with Epilepsy Study Listed on
LEP108937 Completed An open-label, two-cohort study to assess the effect of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy subjects Study Listed on
LEP111102 Completed A Pivotal, Single-Dose, Randomised, Parallel-Group, Open-Label Study to Demonstrate Bioequivalence of 250mg Lamotrigine XR relative to 200mg + 50mg Lamotrigine XR and to Demonstrate Lack of Food Effect on 250mg Lamotrigine XR in Healthy Male and Female Volunteers Study Listed on
LEV102341 Completed A national, multicentric, randomised, controlled trial. Applications of a critical pathway using Levofloxacin for the management of patients with abnormal PSA.
LEX106430 Completed A Phase IIIB, randomized, open-label, parallel group, multi-center, non-inferiority, 24-week study to evaluate the safety, efficacy and tolerability of switching from a 200mg ritonavir-boosted regimen of LEXIVA (700mg/100mg BID or 1400mg/200mg QD) to a once-daily, 100mg ritonavir-boosted regimen of LEXIVA (1400mg/100mg QD)
LP2105521 Completed A multicenter, randomized, 12 week, double-blind, placebo-controlled, parallel-group, Phase IIa study using 18F fluorodeoxyglucose (FDG)-PET to measure the effects of rilapladib on macrophage activity in subjects with atherosclerosis Study Listed on
LP2108364 Completed A Double Blind, Placebo controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers
LP4110001 Completed A Randomised, Single Blind, 2 Period, Crossover Study to Compare the Single Dose Pharmacokinetics and Tolerability of Formulations Containing Unmilled and Micronised SB-568859 in Healthy Adults
LPL104884 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of SB-480848, an oral lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in subjects with stable coronary heart disease (CHD) or CHD-risk equivalent to examine chronic inhibition of Lp-PLA2 effects on circulating biomarkers associated with cardiovascular risk, safety and tolerability over 12 weeks Study Listed on
LPL107629 Completed A randomised, double-blind, placebo-controlled, parallel group, repeat dose study to assess the effect of SB-480848 on overall asthma control in adult subjects with persistent asthma controlled on stable, low-dose, inhaled corticosteroids Study Listed on
LPL110077 Completed A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of darapladib (SB480848) in healthy Japanese male subjects Study Listed on
LPL110118 Completed A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A multicenter, randomized, double-blind, placebo-controlled study of SB-480848 to evaluate the Efficacy and Safety - Study Listed on
LPL110736 Completed Phase I study of SB-480848 (darapladib) -A double blind, randomised, placebo-controlled, parallel-group, repeat dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-480848 in healthy Japanese male subjects- Study Listed on
LPL111814 Completed An Open Label, Single Session Study to Collect Tolerability Information Following Repeat Dosing of Darapladib in Healthy Adult Subjects Study Listed on



For more information on this register please email

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party. is a database that provides summary protocol information for ongoing clinical trials. is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.